Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
LONG-ACTING EXENDIN-4 AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2020/116847
Kind Code:
A1
Abstract:
The present invention relates to a long-acting exendin-4 in which an albumin binding domain (ABD) and an anti-FcRn affibody are fused to exendin-4, and a use thereof. A long-acting exendin-4 according to the present invention has an in vivo half-life that is significantly increased over that of exendin-4, which is conventionally used as an agent for treating diabetes, and resultantly acts as a diabetes therapeutic agent, which is a conventional use of exendin-4, and also exhibits both an effect of treating other metabolic diseases and diabetes complications, such as obesity and fatty liver, and an effect of alleviating cognitive disorders caused by metabolic diseases.

Inventors:
ROH GU SEOB (KR)
SHIN MEONG CHEOL (KR)
LEE JONG YOUL (KR)
PARK TAEHOON (KR)
Application Number:
PCT/KR2019/016412
Publication Date:
June 11, 2020
Filing Date:
November 27, 2019
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
NAT UNIV GYEONGSANG IACF (KR)
International Classes:
A23L33/18; C07K14/605; A61K38/26; A61K47/64; A61K47/68; A61P25/18; C07K16/28; C12N15/70
Foreign References:
JP2016188225A2016-11-04
KR20170037564A2017-04-04
US20140170142A12014-06-19
KR20150016585A2015-02-12
KR20170054440A2017-05-17
Attorney, Agent or Firm:
LEE, Cheo Young et al. (KR)
Download PDF: